World Allergy Organization Journal最新文献

{"title":"Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review","authors":"Freda Yang MBChB MD(Res) ,&nbsp;Justin D. Salciccioli MBBS MA ,&nbsp;Rhea E. Patel BSc ,&nbsp;Marcus McClean MBChB ,&nbsp;Chloe I. Bloom MBBS PhD","doi":"10.1016/j.waojou.2025.101155","DOIUrl":"10.1016/j.waojou.2025.101155","url":null,"abstract":"<div><h3>Background</h3><div>Biologic therapies improve outcomes in severe asthma, but eligibility criteria vary globally, influencing the proportion of patients who qualify. We systematically reviewed studies to estimate the global prevalence of biologic eligibility in patients aged ≥12 years with American Thoracic Society / European Respiratory Society (ATS/ERS)-defined severe asthma and the proportion eligible for each biologic.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines (PROSPERO CRD42023393897), we searched MEDLINE, EMBASE, Web of Science, and ClinicalTrials.gov for studies published between 2000 and 2025 that reported the proportion of biologic-naïve, severe asthma patients eligible for omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab. Two reviewers independently screened studies, extracted data on eligibility proportions and criteria, and assessed quality using the AXIS tool.</div></div><div><h3>Results</h3><div>Ten observational studies, including 3500 patients with ATS/ERS-defined severe asthma, met the inclusion criteria. Across all studies, 1770 patients (51%) were eligible for at least 1 biologic, though estimates ranged widely from 24% to 91%, largely reflecting differences in national eligibility criteria. Omalizumab eligibility was reported in 8 studies (16%, range 6%–66%), mepolizumab in 9 studies (27%, 19%–78%), benralizumab in 6 studies (25%, 19%–53%), reslizumab in 6 studies (17%, 6%–41%), and dupilumab in 2 studies (41%, 37%–75%). No study assessed tezepelumab. Overall, the lowest eligibility (24%) was reported in the European IDEAL cohort due to stringent exacerbation and biomarker criteria, whereas the highest (91%) was observed in a Canadian single-centre cohort using less restrictive national regulatory criteria.</div></div><div><h3>Conclusion</h3><div>Globally, approximately 51% of adults with severe asthma are eligible for biologic therapy, excluding tezepelumab. Among available biologics, eligibility is generally higher for anti-IL5/IL5Rα therapies than for anti-IgE, and appears highest for anti-IL4Rα, although data for the latter remain limited.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101155"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and allergen sensitisation in patients undergoing prick testing","authors":"Olga Patricia Monge Ortega MD, MSc ,&nbsp;Ignacio Rivero Gairaud MD ,&nbsp;Giovanni Sedó Mejía MD","doi":"10.1016/j.waojou.2025.101133","DOIUrl":"10.1016/j.waojou.2025.101133","url":null,"abstract":"<div><h3>Background</h3><div>Epidemiological data on allergen sensitisation in Costa Rica are limited, while prevalence of allergic diseases in the world is rising. This study aims to determine the epidemiology and patterns of allergen sensitisation in patients who underwent prick testing.</div></div><div><h3>Methods</h3><div>A retrospective descriptive-observational study was conducted, including 1001 patients aged &gt;12 years undergoing prick testing between 2019 and 2021. Descriptive statistics were used to collect data on demographics, aeroallergens and food sensitisation.</div></div><div><h3>Results</h3><div>The study population had a mean age of 35.9 ± 16.3 years and was predominantly female. Most patients were from San José, with chronic rhinitis being the most common pre-test diagnosis. Mites (<em>Dermatophagoides farinae</em>, <em>Dermatophagoides pteronissinus</em>), feline epithelium and cockroach mixture were the most common aeroallergens, while shrimp and shellfish were the main food allergens. A significant increase in sensitisation was observed in patients with pre-existing allergic conditions.</div></div><div><h3>Conclusion</h3><div>The results underline the high prevalence of allergen sensitisation in patients with allergic diseases in Costa Rica, especially in urban areas, and highlight the importance of allergen identification for effective management and prevention.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101133"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient preference in allergen immunotherapy - Understanding the patient's view","authors":"Sven Becker MD ,&nbsp;Martin Feindor MD ,&nbsp;Anke Graessel PhD ,&nbsp;Isabel Fernández de Alba MD ,&nbsp;Katrin Birkholz PhD ,&nbsp;Jennifer Raab PhD ,&nbsp;Filippo Fassio MD ,&nbsp;Dolores Hernandez MD ,&nbsp;Neil Valentine Mr. ,&nbsp;Robin Abro Mr. ,&nbsp;Oliver Fuchs MD ,&nbsp;Simon Blank PhD ,&nbsp;Markus Ollert MD ,&nbsp;David Gonzalez-de-Olano MD ,&nbsp;Ludger Klimek MD ,&nbsp;Erika Jensen-Jarolim MD ,&nbsp;Peter Schmid-Grendelmeier MD ,&nbsp;Gerald Hofer PhD ,&nbsp;Matthias F. Kramer MD","doi":"10.1016/j.waojou.2025.101154","DOIUrl":"10.1016/j.waojou.2025.101154","url":null,"abstract":"<div><h3>Background</h3><div>Allergen Immunotherapy (AIT) is an effective treatment for patients with pollen, house dust mite, or venom allergy, but treatment adherence can be challenging. Patient preferences play a crucial role in acceptance and adherence to AIT, but little is known about these preferences. This study aimed to understand patient preferences for AIT and how these preferences influence treatment acceptance.</div></div><div><h3>Methods</h3><div>A conjoint analysis was conducted among 750 participants from 7 European countries who were allergic to pollen (n = 700) or Hymenoptera venom (n = 50) and had not previously received AIT. Participants were asked to choose between hypothetical AIT products with different attributes, including product type, initial up-dosing posology, potential future risks, and side effects. The relative importance of each attribute was calculated, and sensitivity analyses were performed to assess the impact of specific attribute levels on patient preference.</div></div><div><h3>Results</h3><div>Potential future risk is the attribute with the strongest impact on the importance score for patient preference in both pollen (44%) and venom (41%) allergic patients, followed by side effects (24% for pollen and 35% for venom allergy). Product type was less important, with a 22% importance score in both populations, and dosing schedules were not important at all, with a 2% importance score for pollen and an 11% importance score for venom-allergic patients. Accumulation of foreign material/substance in the body had the largest negative impact on patient preference, with drops of −24.7% (pollen) and −23.6% (venom), respectively.</div></div><div><h3>Conclusions</h3><div>Understanding patient preferences is essential for optimizing the design and delivery of AIT. Different side effects and risk profiles of AIT products can influence patient treatment acceptance the most, and healthcare professionals may not always be aware of it. Future research should focus on developing AIT products that align with patient preferences with simultaneously very high effectiveness to improve adherence and treatment outcomes.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101154"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in the efficacies of commonly used asthma questionnaires for predicting asthma-related outcomes among elderly and non-elderly patients in Japan","authors":"Kazufumi Takada MD, PhD ,&nbsp;Maho Suzukawa MD, PhD ,&nbsp;Hiroyuki Tashimo MD, PhD ,&nbsp;Nobuharu Ohshima MD, PhD ,&nbsp;Masaki Ishii MD, PhD ,&nbsp;Ken Ohta MD, PhD ,&nbsp;the NHOM-Asthma study group","doi":"10.1016/j.waojou.2025.101131","DOIUrl":"10.1016/j.waojou.2025.101131","url":null,"abstract":"<div><h3>Background</h3><div>Elderly asthma (EA) and non-elderly asthma (NEA) have been shown to differ greatly. The aim of this study was therefore to identify any differences in the abilities of commonly used asthma questionnaires to predict asthma outcomes in patients with EA and those with NEA, and to further determine the questions that are important for outcome prediction.</div></div><div><h3>Methods</h3><div>This study analyzed data from the NHOM-Asthma study, a nationwide asthma registry in Japan which included 1014 patients with EA (aged ≥65 years) and 842 with NEA (aged &lt;65 years). The correlations between total scores or individual items of the Asthma Control Questionnaire 6 (ACQ6), Asthma Quality of Life Questionnaire (AQLQ), and Asthma Starts with Knowledge 20, and asthma-related outcomes (unscheduled hospital visits, acute exacerbations, admissions within 1 year, and pulmonary function test results) were analyzed.</div></div><div><h3>Results</h3><div>Worse baseline ACQ6 and AQLQ scores were significantly correlated with worse asthma-related outcomes in patients with NEA. In contrast, in patients with EA, these scores and the individual question items showed only a weak or no correlation with asthma-related outcomes. Instead, specific questions related to wheezing, nocturnal symptoms, nasal symptoms, and activity limitations were found to be closely associated with asthma-related outcomes in patients with EA. Moreover, the oscillometry data may better reflect the severity of asthma symptoms and activity limitations, as assessed by questionnaires, than spirometry data, including the forced expiratory volume in 1 sec, in patients with EA.</div></div><div><h3>Conclusions</h3><div>Commonly used asthma questionnaires may not be suitable for predicting outcomes in patients with EA. However, specific questions addressing factors such as wheezing, nocturnal symptoms, nasal issues, and activity limitations may serve as reliable indicators of asthma-related outcomes in these patients.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101131"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global disparities in adrenaline access: A World Allergy Organization call for equity in anaphylaxis care","authors":"Mário Morais-Almeida MD ,&nbsp;Bryan L. Martin DO ,&nbsp;Paul J. Turner PhD ,&nbsp;Alessandro Fiocchi MD ,&nbsp;Motohiro Ebisawa MD, PhD ,&nbsp;Gary Wing-Kin Wong MD ,&nbsp;Ignacio J. Ansotegui MD, PhD ,&nbsp;Maryam Ali Al-Nesf Al-Mansouri MD, ABHS, MScR ,&nbsp;Jonathan A. Bernstein MD ,&nbsp;Hiroshi Chantaphakul MD ,&nbsp;Tinatin Chikovani MD, PhD ,&nbsp;Mary Beth Fasano MD, MSPH ,&nbsp;Luz Fonacier MD ,&nbsp;Pedro Giavina-Bianchi MD, PhD ,&nbsp;René Maximiliano Gómez MD, PhD ,&nbsp;Sandra N. González-Díaz MD, PhD ,&nbsp;Elham Hossny MD, PhD ,&nbsp;David M. Lang MD ,&nbsp;Hideaki Morita MD ,&nbsp;José Antonio Ortegal Martell MD ,&nbsp;Luciana Kase Tanno MD, PhD","doi":"10.1016/j.waojou.2025.101141","DOIUrl":"10.1016/j.waojou.2025.101141","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101141"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaphylaxis and pregnancy: Epidemiology, elicitors, and recurrences","authors":"Luciana Kase Tanno MD, PhD ,&nbsp;Pham Thao Van Luong MD, MSc ,&nbsp;Megane Dieval MSc ,&nbsp;Caroline Dunoyer PhD ,&nbsp;Emma Di Meglio MSc ,&nbsp;Florent Fuchs MD, PhD ,&nbsp;Nicolas Molinari PhD ,&nbsp;Isabella Annesi-Maesano MD, PhD ,&nbsp;Pascal Demoly MD, PhD","doi":"10.1016/j.waojou.2025.101149","DOIUrl":"10.1016/j.waojou.2025.101149","url":null,"abstract":"<div><h3>Background</h3><div>Anaphylaxis during pregnancy implies a risk to both mothers and newborns. However, limited data are available. Therefore, our aim is to explore patterns of hospital admissions diagnosed with anaphylaxis in pregnant women in France from 2012 to 2021, using a national hospital billing database and to evaluate potential determinants, trends and recurrences.</div></div><div><h3>Methods</h3><div>Descriptive study using data from the French Program for the Medicalization of Information Systems, from 2012 to 2021. We included all patients hospitalized for anaphylaxis using International Classification of Diseases (ICD)-10 codes listed as a primary diagnosis. Two groups of patients were included: pregnant (PW) and non-pregnant women (NPW), adjusted by age. Severe anaphylaxis (SA) was defined based on the need of admissions in intensive care units. Sankey graphics were employed to visualize data related to recurrences.</div></div><div><h3>Results</h3><div>During a nine-year study period, 37,962 female patients had 42,399 admissions due to anaphylaxis for all causes. We evaluated data from 734 admissions for anaphylaxis experienced by 653 PW. In both groups 65% of cases were unspecified anaphylaxis, with high number of recurrences. PW experienced higher proportion of SA (8.7%, 95%CI [6.8%, 11.1%]) and recurrences (1.51, 95%CI [1.3, 1,7]), compared with NPW. Most of SA in PW was triggered by drugs (23%, 95%CI [22.3%, 23.6%]). Different from NPW, no seasonal trend was observed in the PW group. From all 670 PW who experienced non-SA, 0.33% (95% CI 0.09–1.2) evolved with SA, and 0.92% (95% CI 0.42–1.99) were admitted for different etiologies in forthcoming admissions.</div></div><div><h3>Conclusion</h3><div>Beyond providing a snapshot of characteristics of anaphylaxis during pregnancy in France, we were able to explore trends and recurrence of anaphylaxis in this population. Although further research is needed in the field, we strongly believe that the data presented contributed as a starting point of public health advancements to ensure quality of care of patients suffering from anaphylaxis.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101149"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering the diagnostic potential of thyroperoxidase autoantibodies in chronic spontaneous urticaria","authors":"Parth Aphale PhD,&nbsp;Himanshu Shekhar BHMS,&nbsp;Shashank Dokania BHMS","doi":"10.1016/j.waojou.2025.101144","DOIUrl":"10.1016/j.waojou.2025.101144","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101144"},"PeriodicalIF":4.3,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reframing the immunopathogenic role of anti-TPO autoantibodies in chronic spontaneous urticaria: Toward a unified IgE–IgG axis hypothesis","authors":"Nav La MD, PhD ,&nbsp;Schawanya K. Rattanapitoon MD ,&nbsp;Natthawut Charoenphon BSc, PhD ,&nbsp;Nathkapach K. Rattanapitoon BSc(PH), BSc(OSH), MSc, PhD","doi":"10.1016/j.waojou.2025.101138","DOIUrl":"10.1016/j.waojou.2025.101138","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 11","pages":"Article 101138"},"PeriodicalIF":4.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145529119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unequal contributions in global allergy research: A comparative study of high-, low-, and middle-income countries","authors":"Andrés Noyola-Pérez MD ,&nbsp;Sandra Nora Gonzalez-Diaz MD, PhD ,&nbsp;Carlos Macouzet-Sanchez MD, PhD ,&nbsp;Alejandra Macías-Weinnmann MD ,&nbsp;Rosa I. Guzmán-Avilán MD, PhD ,&nbsp;Cindy E. de Lira-Quezada MD, PhD ,&nbsp;Ana K. Chavez-Ruiz MD ,&nbsp;Mario Morais-Almeida MD ,&nbsp;Byran Martin MD ,&nbsp;Ignacio J. Ansotegui MD, PhD ,&nbsp;Mariana Castillo-Rubio MD","doi":"10.1016/j.waojou.2025.101130","DOIUrl":"10.1016/j.waojou.2025.101130","url":null,"abstract":"<div><h3>Introduction</h3><div>Global disparities in scientific research disproportionately favor high-income countries (HICs), limiting contributions from low- and middle-income countries (LMICs). In allergology, this inequity restricts diverse perspectives and constrains advancements in addressing allergic diseases, which disproportionately affects underserved populations.</div></div><div><h3>Methods</h3><div>This study analyzed the contributions of 41 allergy journals listed in the 2024 <em>Journal Citation Reports</em>. Data on publication volume, citation impact, article processing charges (APCs), and editorial board representation were collected. Countries were classified as HICs or LMICs based on World Bank rankings. Descriptive statistics and comparative analyses were used to evaluate the disparities between HICs and LMICs.</div></div><div><h3>Results</h3><div>LMICs accounted for only 18.6% of the total publications, compared to a median of 85% from HICs, and only 1 journal included a low-income country among its top contributors. Journals received contributions from a median of 8 HICs versus 2 LMICs. APCs presented a median cost of 3090 USD, posing a significant financial barrier. Geographic alignment was observed between editorial boards and contributing countries, further limiting LMIC representation.</div></div><div><h3>Conclusion</h3><div>Systemic barriers, including high APCs numbers and underrepresentation on editorial boards, limit the contribution in global allergology. Addressing these disparities requires reducing financial obstacles, expanding capacity-building initiatives, and ensuring equitable editorial representation. Creating inclusive research ecosystems can enhance global knowledge dissemination and improve outcomes for populations disproportionately affected by allergic diseases.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 11","pages":"Article 101130"},"PeriodicalIF":4.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145425356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes of acute eosinophilic pneumonia: A nationwide descriptive study","authors":"Tomohiro Akaba MD, PhD, MPH ,&nbsp;Yuya Kimura MD, MPH ,&nbsp;Mitsuko Kondo MD, PhD ,&nbsp;Hiroki Matsui PhD, MPH ,&nbsp;Kiyohide Fushimi MD, PhD ,&nbsp;Etsuko Tagaya MD, PhD ,&nbsp;Hideo Yasunaga MD, PhD","doi":"10.1016/j.waojou.2025.101139","DOIUrl":"10.1016/j.waojou.2025.101139","url":null,"abstract":"<div><div>Acute eosinophilic pneumonia (AEP) is a rare lung disease marked by rapid respiratory failure and eosinophilic infiltration of the lungs. Despite its clinical importance, limited data exist on the characteristics and outcomes of AEP in the general population. We conducted a nationwide study using the Japanese Diagnosis Procedure Combination database from April 2020 to March 2023. Patients with AEP were identified based on diagnostic codes and bronchoscopy records, and we evaluated their clinical characteristics, treatments, and outcomes. A total of 328 patients were included. The median age was 46 years, and 63.7% were male. Hypoxia was present in 86.9% of patients at admission. Systemic corticosteroids were administered to 96% of patients, with 37.5% receiving pulse therapy. Mechanical ventilation was required in 4.9% of cases, and 7.3% of patients were admitted to intensive or high-care units. The median hospital stay was 11 days, and in-hospital mortality was 1.2%. Patients with hypoxia at admission had longer hospital stays and received higher doses of corticosteroids and empirical antibiotics (p &lt; 0.001 for each). No disease-related readmissions were reported after discharge. These findings suggest that most AEP patients have favorable short-term outcomes, although those with hypoxia at admission may require more intensive treatment.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 11","pages":"Article 101139"},"PeriodicalIF":4.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145529124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}